Skip to main content
Fig. 1 | Respiratory Research

Fig. 1

From: Effect of indacaterol/glycopyrronium on ventilation and perfusion in COPD: a randomized trial

Fig. 1

A Study design. This was a randomized, double-blind, placebo-controlled, two-period crossover study of approximately 8 weeks and consisted of 7 periods. B Study disposition. A total of 122 patients were screened, of whom 31 were randomized to one of two treatment sequences. Two patients did not complete both treatment period I and II due to SAEs (one atrial fibrillation and one femoral neck fracture). Screen failures relating to inclusion/exclusion criteria primarily included clinically significant electrocardiogram abnormalities, abnormal computed tomography scan, ineligible pulmonary function test results, or COPD exacerbation. IND/GLY indacaterol/glycopyrronium, MRI magnetic resonance imaging, PD pharmacodynamics, SAE serious adverse event

Back to article page